AcceleDev Chemical LLC, a leading provider of custom synthesis services worldwide, has announced the opening of its new 5,000-square-foot R&D and GMP production facility at 1 Duncan Drive, Cranbury, New Jersey. This expansion marks a significant milestone in AcceleDev’s mission to offer advanced chemistry solutions and support the creation of new medications. Established in 2003 by Charlie Lewis, AcceleDev Chemical LLC has been a pioneer in custom synthesis, delivering inventive solutions to pharmaceutical companies globally. With the addition of this new facility, AcceleDev aims to strengthen its capabilities in the research and production of early development active ingredients and intermediates, with a focus on serving the U.S. pharmaceutical market.
Charlie Lewis, Founder and Managing Director of AcceleDev Chemical LLC, expressed his excitement about the new facility:
“This expansion is a testament to our commitment to innovation and excellence in chemistry. Our new lab in Cranbury not only increases our capacity but also strengthens our ability to support our partners in bringing new medicines to the market efficiently and safely.”
Dr. Dave Tschaen, Chief Scientific Officer, who joined AcceleDev after a distinguished career at Merck Pharmaceutical, highlighted features of the new lab:
“Our new facility will be equipped with GMP suites and cutting-edge technology, allowing us to perform high-level R&D and small-scale production under stringent quality standards. This move not only enhances our technical capabilities but also ensures that we continue to meet the expectations of our customers in delivering safe and effective pharmaceutical solutions.”
AcceleDev has decided to move to a larger laboratory space in order to expand its chemistry R&D and GMP small-scale production capabilities in the USA. This expansion will enable AcceleDev to become a higher-level active ingredient small-scale producer and better support the introduction of new medicines to the marketplace. The facility’s GMP suites are expected to attract customers for visits, inspections, and approvals, strengthening confidence in AcceleDev’s commitment to quality and compliance.
The new laboratory space includes three process development rooms with 8-ft. hoods, an analytical lab, and two isolated GMP suites. This environment will allow AcceleDev to conduct high-quality research and production, ensuring compliance with the highest industry standards.
AcceleDev Chemical LLC offers a comprehensive range of services. All custom synthesis projects are performed exclusively for customer partners with rigorous protection of intellectual property, and sharing of new chemistry IP developed during projects. The company offers a broad spectrum of capabilities, including full API process route design, development, and scale-up. With expertise in producing complex pharmaceutical targets, AcceleDev can perform synthetic routes of any length, from 1 to 20 steps or greater, and at any scale from mg to MT.
The company’s organization includes 70 chemists, with 12 highly experienced PhDs. Primary Pharma FFS & FTE work is conducted at AcceleDev’s Shanghai and New Jersey R&D sites, while scale-up and commercial projects are executed at its Jiangyin and Dalian production sites in China. The U.S. R&D team is small but rapidly growing, comprising seven chemists, while the Shanghai team includes 40 chemists.
